Influence of FLT3L treatment on lymphocyte subpopulations. C57BL/6 mice were injected intraperitoneally with either 2 or 10 μg, daily, or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice (C). Percentages of Foxp3⁺ cells among CD4SP (top) or absolute numbers of Foxp3⁺ cells (bottom) in thymus of FLT3L KO, WT control, or WT-treated mice. (D) Percentages of Foxp3⁺ cells among CD4 T cell or absolute numbers of Foxp3⁺ cells in spleen of FLT3L KO, WT control, or WT-treated mice. Each bar shows mean ± SEM. *P < .05; **P < .01. FLT3L KO, ; WT control, ; WT treated, and .